<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>oncology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>oncology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="A high throughput blood-based assay for the early detection of pancreatic cancer
Authors: Montoya Mira, J. L.; Quentel, A.; Patel, R. K.; Keith, D.; Minnier, J.; David, L.; Esener, S. C.; Sears, R. C.; Lopez, C. D.; Sheppard, B. C.; Demirci, U.; Wong, M. H.; Fischer, J. M.
Score: 2.0, Published: 2024-01-13 DOI: 10.1101/2024.01.12.24301220
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due in part to the cancer being diagnosed is at a late stage when effective treatment options are limited.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/oncology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="oncology" />
<meta property="og:description" content="A high throughput blood-based assay for the early detection of pancreatic cancer
Authors: Montoya Mira, J. L.; Quentel, A.; Patel, R. K.; Keith, D.; Minnier, J.; David, L.; Esener, S. C.; Sears, R. C.; Lopez, C. D.; Sheppard, B. C.; Demirci, U.; Wong, M. H.; Fischer, J. M.
Score: 2.0, Published: 2024-01-13 DOI: 10.1101/2024.01.12.24301220
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due in part to the cancer being diagnosed is at a late stage when effective treatment options are limited." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/oncology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2024-01-21T10:39:08+00:00" />
<meta property="article:modified_time" content="2024-01-21T10:39:08+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="oncology"/>
<meta name="twitter:description" content="A high throughput blood-based assay for the early detection of pancreatic cancer
Authors: Montoya Mira, J. L.; Quentel, A.; Patel, R. K.; Keith, D.; Minnier, J.; David, L.; Esener, S. C.; Sears, R. C.; Lopez, C. D.; Sheppard, B. C.; Demirci, U.; Wong, M. H.; Fischer, J. M.
Score: 2.0, Published: 2024-01-13 DOI: 10.1101/2024.01.12.24301220
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due in part to the cancer being diagnosed is at a late stage when effective treatment options are limited."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "oncology",
      "item": "https://trxiv.yorks0n.com/posts/oncology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "oncology",
  "name": "oncology",
  "description": "A high throughput blood-based assay for the early detection of pancreatic cancer\nAuthors: Montoya Mira, J. L.; Quentel, A.; Patel, R. K.; Keith, D.; Minnier, J.; David, L.; Esener, S. C.; Sears, R. C.; Lopez, C. D.; Sheppard, B. C.; Demirci, U.; Wong, M. H.; Fischer, J. M.\nScore: 2.0, Published: 2024-01-13 DOI: 10.1101/2024.01.12.24301220\nPancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due in part to the cancer being diagnosed is at a late stage when effective treatment options are limited.",
  "keywords": [
    
  ],
  "articleBody": " A high throughput blood-based assay for the early detection of pancreatic cancer\nAuthors: Montoya Mira, J. L.; Quentel, A.; Patel, R. K.; Keith, D.; Minnier, J.; David, L.; Esener, S. C.; Sears, R. C.; Lopez, C. D.; Sheppard, B. C.; Demirci, U.; Wong, M. H.; Fischer, J. M.\nScore: 2.0, Published: 2024-01-13 DOI: 10.1101/2024.01.12.24301220\nPancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due in part to the cancer being diagnosed is at a late stage when effective treatment options are limited. Early detection of PDAC via liquid biopsy would revolutionize survival from the disease. To address the lack of effective non-invasive detection assays for PDAC, we developed a protease activity-based assay using a magnetic nanosensor (PAC*MANN). The PAC*MANN assay leverages protease activity in blood to amplify the signal of the target-probe based sensor. An initial screening revealed that the PAC*MANN assay could reliably differentiate patients with PDAC from healthy subjects and patients at high risk of PDAC. Finally, in two cohorts: training (n=145) and blinded validation (n=72), we demonstrated that the PAC*MANN assay had high specificity (86%) and sensitivity (78%) for detection of PDAC compared to healthy subjects. This performance was enhanced when combined with the current standard of care assay, CA19-9 (100% specificity, 84% sensitivity). Our results demonstrate a novel assay that is rapid, high-throughput, and requires low specimen volume, which may not only improve cancer detection but could be useful for monitoring of at-risk patients and could be deployed in low resource settings. One sentence summaryA high-throughput, non-invasive, rapid protease-activated nanosensor identifies pancreatic cancer from a small volume of blood\nObesity shapes selection for driver mutations in cancer\nAuthors: Tang, C.; Castillon, V. J.; Waters, M.; Fong, C.; Park, T.; Boscenco, S.; Kim, S.; Schultz, N.; Ostrovnaya, I.; Gusev, A.; Jee, J.; Reznik, E.\nScore: 11.2, Published: 2024-01-11 DOI: 10.1101/2024.01.10.24301114\nObesity is a leading risk factor for cancer, but whether obesity is linked to specific genomic subtypes of cancer is unknown. Here, we examined the relationship between obesity and tumor genotype in two large clinicogenomic corpora. Obesity was associated with specific driver mutations in lung adenocarcinoma, endometrial carcinoma, and cancers of unknown primary, independent of clinical covariates and genetic ancestry. Obesity is therefore a putative driver of etiologic heterogeneity across cancers.\nAnalytical Validation of NeXT Personal (R), an Ultra-sensitive Personalized Circulating Tumor DNA Assay\nAuthors: Northcott, J.; Bartha, G.; Harris, J.; Li, C.; Navarro, F. C. P.; Pyke, R. M.; Hong, M.; Zhang, Q.; Ma, S.; Chen, T. X.; Lai, J.; Udar, N.; Saldivar, J.-S.; Ayash, E.; Anderson, J.; Li, J.; Cui, T.; Le, T.; Chow, R.; Velasco, R.; Mallo, C.; Santiago, R.; Bruce, R. C.; Goodman, L. J.; Chen, Y.; Norton, D.; Chen, R. O.; Lyle, J. M.\nScore: 0.5, Published: 2024-01-17 DOI: 10.1101/2024.01.17.23299863\nWe describe the analytical validation of NeXT Personal(R), an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay for detecting residual disease, monitoring therapy response, and detecting recurrence in patients diagnosed with solid tumor cancers. NeXT Personal uses whole genome sequencing of tumor and matched normal samples combined with advanced analytics to accurately identify up to [~]1,800 somatic variants specific to the patients tumor. A personalized panel is created, targeting these variants and then used to sequence cell-free DNA extracted from patient plasma samples for ultra-sensitive detection of ctDNA. The NeXT Personal analytical validation is based on panels designed from tumor and matched normal samples from two cell lines, and from 123 patients across nine cancer types. Analytical measurements demonstrated a detection threshold of 1.67 parts per million (PPM) with a limit of detection at 95% (LOD95) of 3.45 PPM. NeXT Personal showed linearity over a range of 0.8 to 300,000 PPM (Pearson correlation coefficient= 0.9998). Precision varied from a coefficient of variation of 12.8% to 3.6% over a range of 25 to 25,000 PPM. The assay targets 99.9% specificity, with this validation study measuring 100% specificity and in silico methods giving us a confidence interval of 99.92 to 100%. In summary, this study demonstrates NeXT Personal as an ultra-sensitive, highly quantitative and robust ctDNA assay that can be used to detect residual disease, monitor treatment response, and detect recurrence in patients.\n",
  "wordCount" : "689",
  "inLanguage": "en",
  "datePublished": "2024-01-21T10:39:08Z",
  "dateModified": "2024-01-21T10:39:08Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/oncology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      oncology
    </h1>
    <div class="post-meta">&lt;span&gt;updated on January 21, 2024&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.12.24301220">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.12.24301220" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.12.24301220">
        <p class="paperTitle">A high throughput blood-based assay for the early detection of pancreatic cancer</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.12.24301220" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.12.24301220" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Montoya Mira, J. L.; Quentel, A.; Patel, R. K.; Keith, D.; Minnier, J.; David, L.; Esener, S. C.; Sears, R. C.; Lopez, C. D.; Sheppard, B. C.; Demirci, U.; Wong, M. H.; Fischer, J. M.</p>
        <p class="info">Score: 2.0, Published: 2024-01-13 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.12.24301220' target='https://doi.org/10.1101/2024.01.12.24301220'> 10.1101/2024.01.12.24301220</a></p>
        <p class="abstract">Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due in part to the cancer being diagnosed is at a late stage when effective treatment options are limited. Early detection of PDAC via liquid biopsy would revolutionize survival from the disease. To address the lack of effective non-invasive detection assays for PDAC, we developed a protease activity-based assay using a magnetic nanosensor (PAC*MANN). The PAC*MANN assay leverages protease activity in blood to amplify the signal of the target-probe based sensor. An initial screening revealed that the PAC*MANN assay could reliably differentiate patients with PDAC from healthy subjects and patients at high risk of PDAC. Finally, in two cohorts: training (n=145) and blinded validation (n=72), we demonstrated that the PAC*MANN assay had high specificity (86%) and sensitivity (78%) for detection of PDAC compared to healthy subjects. This performance was enhanced when combined with the current standard of care assay, CA19-9 (100% specificity, 84% sensitivity). Our results demonstrate a novel assay that is rapid, high-throughput, and requires low specimen volume, which may not only improve cancer detection but could be useful for monitoring of at-risk patients and could be deployed in low resource settings.

One sentence summaryA high-throughput, non-invasive, rapid protease-activated nanosensor identifies pancreatic cancer from a small volume of blood</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.10.24301114">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.10.24301114" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.10.24301114">
        <p class="paperTitle">Obesity shapes selection for driver mutations in cancer</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.10.24301114" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.10.24301114" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Tang, C.; Castillon, V. J.; Waters, M.; Fong, C.; Park, T.; Boscenco, S.; Kim, S.; Schultz, N.; Ostrovnaya, I.; Gusev, A.; Jee, J.; Reznik, E.</p>
        <p class="info">Score: 11.2, Published: 2024-01-11 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.10.24301114' target='https://doi.org/10.1101/2024.01.10.24301114'> 10.1101/2024.01.10.24301114</a></p>
        <p class="abstract">Obesity is a leading risk factor for cancer, but whether obesity is linked to specific genomic subtypes of cancer is unknown. Here, we examined the relationship between obesity and tumor genotype in two large clinicogenomic corpora. Obesity was associated with specific driver mutations in lung adenocarcinoma, endometrial carcinoma, and cancers of unknown primary, independent of clinical covariates and genetic ancestry. Obesity is therefore a putative driver of etiologic heterogeneity across cancers.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.17.23299863">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.17.23299863" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.17.23299863">
        <p class="paperTitle">Analytical Validation of NeXT Personal (R), an Ultra-sensitive Personalized Circulating Tumor DNA Assay</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.17.23299863" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.17.23299863" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Northcott, J.; Bartha, G.; Harris, J.; Li, C.; Navarro, F. C. P.; Pyke, R. M.; Hong, M.; Zhang, Q.; Ma, S.; Chen, T. X.; Lai, J.; Udar, N.; Saldivar, J.-S.; Ayash, E.; Anderson, J.; Li, J.; Cui, T.; Le, T.; Chow, R.; Velasco, R.; Mallo, C.; Santiago, R.; Bruce, R. C.; Goodman, L. J.; Chen, Y.; Norton, D.; Chen, R. O.; Lyle, J. M.</p>
        <p class="info">Score: 0.5, Published: 2024-01-17 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.17.23299863' target='https://doi.org/10.1101/2024.01.17.23299863'> 10.1101/2024.01.17.23299863</a></p>
        <p class="abstract">We describe the analytical validation of NeXT Personal(R), an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay for detecting residual disease, monitoring therapy response, and detecting recurrence in patients diagnosed with solid tumor cancers. NeXT Personal uses whole genome sequencing of tumor and matched normal samples combined with advanced analytics to accurately identify up to [~]1,800 somatic variants specific to the patients tumor. A personalized panel is created, targeting these variants and then used to sequence cell-free DNA extracted from patient plasma samples for ultra-sensitive detection of ctDNA.

The NeXT Personal analytical validation is based on panels designed from tumor and matched normal samples from two cell lines, and from 123 patients across nine cancer types. Analytical measurements demonstrated a detection threshold of 1.67 parts per million (PPM) with a limit of detection at 95% (LOD95) of 3.45 PPM. NeXT Personal showed linearity over a range of 0.8 to 300,000 PPM (Pearson correlation coefficient= 0.9998). Precision varied from a coefficient of variation of 12.8% to 3.6% over a range of 25 to 25,000 PPM. The assay targets 99.9% specificity, with this validation study measuring 100% specificity and in silico methods giving us a confidence interval of 99.92 to 100%.

In summary, this study demonstrates NeXT Personal as an ultra-sensitive, highly quantitative and robust ctDNA assay that can be used to detect residual disease, monitor treatment response, and detect recurrence in patients.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2024 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
